样式: 排序: IF: - GO 导出 标记为已读
-
Combined, yet separate: cocktails of carriers (not drugs) for actinium-225 α-particle therapy of solid tumors expressing moderate-to-low levels of targetable markers Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-20 Rajiv Ranjit Nair, Aprameya Prasad, Omkar Bhatavdekar, Aira Sarkar, Kathleen L. Gabrielson, Stavroula Sofou
-
The role of [18 F]FDOPA PET as an adjunct to conventional MRI in the diagnosis of aggressive glial lesions Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-19 Adeline Zinsz, Celso Pouget, Fabien Rech, Luc Taillandier, Marie Blonski, Samir Amlal, Laetitia Imbert, Timothée Zaragori, Antoine Verger
-
B-Glycine as a marker for β cell imaging and β cell mass evaluation Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-18 Yuxiang Han, Hui Liu, Yimin Li, Zhibo Liu
-
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-18 Hong Song, Maria Isabel Leonio, Valentina Ferri, Heying Duan, Carina Mari Aparici, Guido Davidzon, Benjamin L. Franc, Farshad Moradi, Jagruti Shah, Colin P. Bergstrom, Alice C. Fan, Sumit Shah, Ali Raza Khaki, Sandy Srinivas, Andrei Iagaru
-
Cadherin-17 as a target for the immunoPET of adenocarcinoma Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-16 Samantha Delaney, Outi Keinänen, Dennis Lam, Andrew L. Wolfe, Takao Hamakubo, Brian M. Zeglis
-
Intraoperative image-guidance during robotic surgery: is there clinical evidence of enhanced patient outcomes? Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-12 Stefano Tappero, Giuseppe Fallara, Francesco Chierigo, Andrea Micalef, Francesca Ambrosini, Raquel Diaz, Andrea Dorotei, Edoardo Pompeo, Alessia Limena, Carlo Andrea Bravi, Mattia Longoni, Mattia Luca Piccinelli, Francesco Barletta, Luigi Albano, Elio Mazzone, Paolo Dell’Oglio
-
Visual extended reality tools in image-guided surgery in urology: a systematic review Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-09 Enrico Checcucci, Alberto Piana, Gabriele Volpi, Alberto Quarà, Sabrina De Cillis, Federico Piramide, Mariano Burgio, Juliette Meziere, Edoardo Cisero, Marco Colombo, Gabriele Bignante, Michele Sica, Stefano Granato, Paolo Verri, Cecilia Gatti, Paolo Alessio, Michele Di Dio, Stefano Alba, Cristian Fiori, Daniele Amparore, Francesco Porpiglia
-
PET/CT study of dopamine transporter (DAT) binding with the triple reuptake inhibitor toludesvenlafaxine in rats and humans Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-08 Zhiwei Huang, Junhao Wu, Yihui Guan, Yumei Wei, Fang Xie, Yifeng Shen
-
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-08 Antonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Santiago Escrivà-de-Romani, Agostina Stradella, Manuel Ruiz-Borrego, Begoña Bermejo de las Heras, Marleen Keyaerts, Patricia Galvan, Fara Brasó-Maristany, Juan José García-Mosquera, Thomas Guiot, María Gion, Miguel Sampayo-Cordero, Serena Di Cosimo, Jhudit Pérez-Escuredo, Manuel Atienza de Frutos, Javier Cortés
-
Targeting CXCR4/CXCL12 axis via [177Lu]Lu-DOTAGA.(SA.FAPi)2 with CXCR4 antagonist in triple-negative breast cancer Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-08 Guangfa Bao, Ziqiang Wang, Luoxia Liu, Buchuan Zhang, Shuang Song, Dongdong Wang, Siyuan Cheng, Eu-Song Moon, Frank Roesch, Jun Zhao, Bo Yu, Xiaohua Zhu
-
An ultra-small organic dye nanocluster for enhancing NIR-II imaging-guided surgery outcomes Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-06 Yajun Wang, Ding Zhou, Huilong Ma, Dahai Liu, Yongye Liang, Shoujun Zhu
-
Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-04
Abstract Purpose A probe for targeted alpha therapy (TAT) using the RGD peptide (Ga-DOTA-K([211At]APBA)-c(RGDfK) ([211At]1)) with albumin-binding moiety (ABM) was recently developed. [211At]1 highly accumulated in tumors and significantly inhibited tumor growth in U-87 MG tumor-bearing mice. However, high [211At]1 retention in blood may cause critical adverse events, such as hematotoxicity. Therefore
-
Highlights of the 36th EANM Annual Congress 2023, from hometown Vienna, Austria: “A SYMPHONY OF SCIENCE” Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-04 David Kersting, Silvia Morbelli, Sophie E. M. Veldhuijzen van Zanten, Hein J. Verberne
-
Disrupted gut microecology after high-dose 131I therapy and radioprotective effects of arachidonic acid supplementation Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-02
Abstract Background Despite the potential radiotoxicity in differentiated thyroid cancer (DTC) patients with high-dose 131I therapy, the alterations and regulatory mechanisms dependent on intestinal microecology remain poorly understood. We aimed to identify the characteristics of the gut microbiota and metabolites in DTC patients suffering from high-dose 131I therapy and explore the radioprotective
-
Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™ Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-02
Abstract Purpose Pluvicto™ ([177Lu]Lu-PSMA-617), a radioligand therapeutic targeting prostate-specific membrane antigen (PSMA), has been recently approved for the treatment of metastatic castration-resistant prostate cancer (mCRPR). The drug suffers from salivary gland and kidney uptake that prevents its dose escalation to potentially curative doses. In this work, we sought to potentiate the in vivo
-
Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-02 Yuekai Li, Shiwei Wang, Shimin Zhao, Pengfei Zhao, Shuai Huang, Kaiyue Li, Shaoli Han, Caixia Tian, Xin Li, Benkang Shi, Xiang Li
Purpose Positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) targeting tracers has emerged as a valuable diagnostic tool for prostate cancer (PCa), androgen deprivation therapy (ADT) stands as the cornerstone treatment for advanced PCa, yet forecasting the response to hormonal therapy poses a significant clinical hurdle. Methods In a prospective cohort of 86 PCa patients
-
Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013 Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-02
Abstract Fibroblast activation protein (FAP) has emerged as a highly promising target for cancer diagnostic imaging and targeted radionuclide therapy. To exploit the therapeutic potential of suitably radiolabeled FAP inhibitors (FAPIs), this study presents the design and synthesis of a series of FAPI dimers to increase tumor uptake and retention. Preclinical evaluation and a pilot clinical PET imaging
-
The status of nuclear medicine in China: the first official national survey Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-02
Abstract Aim/introduction The National Nuclear Medicine Quality Control Center of China conducted the first official survey to investigate the nationwide situation of nuclear medicine in 2020. The survey aimed to unveil the current nuclear medicine situation and its quality control in China. Materials and methods The web-based survey was conducted and the data was collected via the National Clinical
-
The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica—a prospective study of 101 patients Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-04-02 Andreas Wiggers Nielsen, Ib Tønder Hansen, Berit Dalsgaard Nielsen, Søren Geill Kjær, Jesper Blegvad-Nissen, Kate Rewers, Christian Møller Sørensen, Ellen-Margrethe Hauge, Lars Christian Gormsen, Kresten Krarup Keller
Purpose 2-[18F]Fluoro-2-deoxy-D-glucose (FDG)–positron emission tomography (PET)/computed tomography (CT) has been suggested as an imaging modality to diagnose polymyalgia rheumatica (PMR). However, the applicability of FDG-PET/CT remains unclear, especially following glucocorticoid administration. This study aimed to investigate the diagnostic accuracy of FDG-PET/CT before and during prednisolone
-
Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer’s disease Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-19 Can Zhou, Fantian Zeng, Haijun Yang, Zeying Liang, Guanyu Xu, Xiao Li, Xingdang Liu, Jian Yang
-
Non-invasive assessment of stimulation-specific changes in cerebral glucose metabolism with functional PET Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-16 Godber Mathis Godbersen, Pia Falb, Sebastian Klug, Leo R. Silberbauer, Murray Bruce Reed, Lukas Nics, Marcus Hacker, Rupert Lanzenberger, Andreas Hahn
-
Early detection of anthracycline-induced cardiotoxicity using [68 Ga]Ga-FAPI-04 imaging Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-16
Abstract Purpose Anthracycline-induced cardiotoxicity (AIC), whose major manifestation is diffuse myocardial fibrosis, is an important clinical problem in cancer therapy. Therefore, early identification and treatment are clinically important. This study aims to explore the feasibility of using 68 Ga-labelled fibroblast activation protein (FAP) inhibitor ([68 Ga]Ga-FAPI) positron emission tomography/computed
-
Diagnostic and prognostic value of dual-point amyloid PET in Alzheimer’s disease (AD) mimickers Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-14 Luca Sofia, Federico Massa, Stefano Raffa, Matteo Pardini, Dario Arnaldi, Matteo Bauckneht, Silvia Morbelli
-
ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-14
Abstract Purpose The cluster of differentiation (CD70) is a potential biomarker of clear cell renal cell carcinoma (ccRCC). This study aims to develop CD70-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging tracers and explore the diagnostic value in preclinical studies and the potential value in detecting metastases in ccRCC patients. Methods Four novel CD70-specific
-
[18F]FDG PET/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-12 Jinbo Gui, Mengting Li, Jia Xu, Xiao Zhang, Heng Mei, Xiaoli Lan
-
[177Lu]Lu-PSMA-617 as first-line systemic therapy in patients with metastatic castration-resistant prostate cancer: a real-world study Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-12 Swayamjeet Satapathy, Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Chandrasekhar Bal
-
Artificial intelligence–based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-08 Christos Sachpekidis, Olof Enqvist, Johannes Ulén, Annette Kopp-Schneider, Leyun Pan, Elias K. Mai, Marina Hajiyianni, Maximilian Merz, Marc S. Raab, Anna Jauch, Hartmut Goldschmidt, Lars Edenbrandt, Antonia Dimitrakopoulou-Strauss
-
Thoracic aortic microcalcification activity in combined positron emission tomography and magnetic resonance imaging Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-08 Jennifer Nash, Samuel Debono, Beth Whittington, Jakub Kaczynski, Tim Clark, Gillian Macnaught, Scott Semple, Edwin J R van Beek, Adriana Tavares, Damini Dey, Michelle C Williams, Piotr J Slomka, David E Newby, Marc R Dweck, Alexander J Fletcher
-
Guiding principles on the education and practice of theranostics Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-08 Thomas N. B. Pascual, Diana Paez, Andrei Iagaru, Gopi Gnanasegaran, Sze Ting Lee, Mike Sathekge, John M. Buatti, Francesco Giammarile, Akram Al-Ibraheem, Manuela Arevalo Pardo, Richard P. Baum, Berardino De Bari, Simona Ben-Haim, Jean-Yves Blay, Anita Brink, Enrique Estrada-Lobato, Stefano Fanti, Anja Tea Golubic, Jun Hatazawa, Ora Israel, Ana Kiess, Peter Knoll, Lizette Louw, Giuliano Mariani, Siroos
Purpose The recent development and approval of new diagnostic imaging and therapy approaches in the field of theranostics have revolutionised nuclear medicine practice. To ensure the provision of these new imaging and therapy approaches in a safe and high-quality manner, training of nuclear medicine physicians and qualified specialists is paramount. This is required for trainees who are learning theranostics
-
First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-07 Julia Fricke, Frida Westerbergh, Lisa McDougall, Chiara Favaretto, Emanuel Christ, Guillaume P. Nicolas, Susanne Geistlich, Francesca Borgna, Melpomeni Fani, Peter Bernhardt, Nicholas P. van der Meulen, Cristina Müller, Roger Schibli, Damian Wild
-
Preoperative evaluation of mediastinal lymph nodes in non-small cell lung cancer using [68Ga]FAPI-46 PET/CT: a prospective pilot study Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-07
Abstract Purpose Mediastinal nodal staging is crucial for surgical candidate selection in non-small cell lung cancer (NSCLC), but conventional imaging has limitations often necessitating invasive staging. We investigated the additive clinical value of fibroblast activation protein inhibitor (FAPI) PET/CT, an imaging technique targeting fibroblast activation protein, for mediastinal nodal staging of
-
Preclinical validation of a novel brain-penetrant PET ligand for visualization of histone deacetylase 6: a potential imaging target for neurodegenerative diseases Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-05 Tetsuro Tago, Muneyuki Sakata, Masakatsu Kanazawa, Shigeyuki Yamamoto, Kenji Ishii, Jun Toyohara
-
Tau aggregation following subcortical hemorrhage Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-03-04 Elena Jaeger, Gérard N. Bischof, Oezguer A. Onur, Marc Schlamann, Alexander Drzezga
-
Dose–effect relationships in neuroendocrine tumour liver metastases treated with [166Ho]-radioembolization Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-19
Abstract Purpose Aim of this study was to investigate a dose-response relationship, dose-toxicity relationship, progression free survival (PFS) and overall survival (OS) in neuroendocrine tumour liver metastases (NELM) treated with holmium-166-microspheres radioembolization ([166Ho]-radioembolization). Materials and methods Single center, retrospective study included patients with NELM that received
-
Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-19 Wenjia Zhang, Xiaolong Liang, Xinyu Zhang, Wei Tong, Guangyuan Shi, Haozhuo Guo, Zhengyu Jin, Jie Tian, Yang Du, Huadan Xue
-
Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-17 Christian Ferschmann, Konstantin Messerschmidt, Johannes Gnörich, Henryk Barthel, Ken Marek, Carla Palleis, Sabrina Katzdobler, Anna Stockbauer, Urban Fietzek, Anika Finze, Gloria Biechele, Jost-Julian Rumpf, Dorothee Saur, Matthias L. Schroeter, Michael Rullmann, Leonie Beyer, Florian Eckenweber, Stephan Wall, Andreas Schildan, Marianne Patt, Andrew Stephens, Joseph Classen, Peter Bartenstein, John
-
EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-17 Caroline Stokke, Silvano Gnesin, Johannes Tran-Gia, Francesco Cicone, Søren Holm, Marta Cremonesi, Johan Blakkisrud, Thomas Wendler, Nic Gillings, Ken Herrmann, Felix M. Mottaghy, Jonathan Gear
-
Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-15 Matteo Cotta Ramusino, Federico Massa, Cristina Festari, Federica Gandolfo, Valentina Nicolosi, Stefania Orini, Flavio Nobili, Giovanni B. Frisoni, Silvia Morbelli, Valentina Garibotto
-
Comparative analysis of [18F]F-FAPI PET/CT, [18F]F-FDG PET/CT and magnetization transfer MR imaging to detect intestinal fibrosis in Crohn’s disease: A prospective animal model and human cohort study Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-15 Zhoulei Li, Zhihui Chen, Ruonan Zhang, Jinjiang Lin, Siyun Huang, Kuangyu Shi, Xiaodi Shen, Zijun Xiang, Xinyue Wang, Lili Huang, Qingzhu Zheng, Xubin Liu, Jinyu Tan, Minhu Chen, Ziping Li, Ren Mao, Xiangsong Zhang, Yangdi Wang, Xinming Song, Xuehua Li
-
Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin’s lymphoma Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-14 Mikhail Ya. Yadgarov, M. M. Dunaykin, G. I. Shestopalov, C. Kailash, E. D. Kireeva, N. V. Myakova, Yu. N. Likar
-
90Y post-radioembolization clinical assessment with whole-body Biograph Vision Quadra PET/CT: image quality, tumor, liver and lung dosimetry Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-13 Konstantinos G. Zeimpekis, Lorenzo Mercolli, Maurizio Conti, Hasan Sari, Axel Rominger, Hendrik Rathke
-
Incorporating the [68Ga]Ga-PSMA PET/CT PRIMARY score into the selection criteria for prostate cancer patients eligible for active surveillance Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-12 Levent Kabasakal, Ruştu Turkay, Bulent Onal
-
Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-10 Meixi Liu, Yuejuan Cheng, Chunmei Bai, Hong Zhao, Ru Jia, Jingci Chen, Wenjia Zhu, Li Huo
-
A patient journey audit tool (PJAT) to assess quality indicators in a nuclear medicine service Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-10
Abstract Purpose To develop a nuclear medicine specific patient journey audit tool (PJAT) to survey and audit patient journeys in a nuclear medicine department such as staff interaction with patients, equipment, quality of imaging and laboratory procedures, patient protection, infection control and radiation safety, with a view to optimising patient care and providing a high-quality nuclear medicine
-
Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial) Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-08 Pim Hendriks, Daphne D. D. Rietbergen, Arian R. van Erkel, Minneke J. Coenraad, Mark J. Arntz, Roel J. Bennink, Andries E. Braat, Stijn Crobach, Otto M. van Delden, Petra Dibbets-Schneider, Tom van der Hulle, Heinz-Josef Klümpen, Rutger W. van der Meer, J. Frank W. Nijsen, Catharina S. P. van Rijswijk, Joey Roosen, Bastian N. Ruijter, Frits Smit, Mette K. Stam, R. Bart Takkenberg, Maarten E. Tushuizen
-
TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images — a multi-center generalizability analysis Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-08 Fereshteh Yousefirizi, Ivan S. Klyuzhin, Joo Hyun O, Sara Harsini, Xin Tie, Isaac Shiri, Muheon Shin, Changhee Lee, Steve Y. Cho, Tyler J. Bradshaw, Habib Zaidi, François Bénard, Laurie H. Sehn, Kerry J. Savage, Christian Steidl, Carlos F. Uribe, Arman Rahmim
-
Preclinical study and first-in-human imaging of [18F]FAP-2286, and comparison with 2-[18F]FDG PET/CT in various cancer patients Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-08 Lifang Liu, Jiawei Zhong, Ziqi Zhang, Xiaoting Ye, Xinlu Wang, Shaoyu Liu, Zhanwen Zhang
-
Preclinical evaluation of 68 Ga-labeled peptide CK2 for PET imaging of NRP-1 expression in vivo Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-06 Qingzhu Liu, Shuyue Cai, Jiacong Ye, Quan Xie, Rongbin Liu, Ling Qiu, Jianguo Lin
-
Guardians of precision: advancing radiation protection, safety, and quality systems in nuclear medicine Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-06 Francesco Giammarile, Peter Knoll, Jolanta Kunikowska, Diana Paez, Enrique Estrada Lobato, Miriam Mikhail-Lette, Richard Wahl, Ola Holmberg, May Abdel-Wahab, Andrew M. Scott, Roberto C. Delgado Bolton
Background In the rapidly evolving field of nuclear medicine, the paramount importance of radiation protection, safety, and quality systems cannot be overstated. This document provides a comprehensive analysis of the intricate regulatory frameworks and guidelines, meticulously crafted and updated by national and international regulatory bodies to ensure the utmost safety and efficiency in the practice
-
Radioiodine versus radiofrequency ablation to treat autonomously functioning thyroid nodules: a systematic review and comparative meta-analysis Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-02 Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček
-
Head-to-head comparison between [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-02-01 Qiao He, Zhengkun Zhang, Linqi Zhang, Bing Zhang, Yali Long, Yuying Zhang, Zhihong Liao, Zhihao Zha, Xiangsong Zhang
-
Correction to: Radiosynthesis and biological evaluation of [18F]AG-120 for PET imaging of the mutant isocitrate dehydrogenase 1 in glioma Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-22 Thu Hang Lai, Barbara Wenzel, Sladjana Dukić-Stefanović, Rodrigo Teodoro, Lucie Arnaud, Aurélie Maisonial-Besset, Valérie Weber, Rareş-Petru Moldovan, Sebastian Meister, Jens Pietzsch, Klaus Kopka, Tareq A. Juratli, Winnie Deuther-Conrad, Magali Toussaint
-
The spatial extent of tauopathy on [18F]MK-6240 tau PET shows stronger association with cognitive performances than the standard uptake value ratio in Alzheimer’s disease Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-17
Abstract Purpose [18F]MK-6240, a second-generation tau PET tracer, is increasingly used for the detection and the quantification of in vivo cerebral tauopathy in Alzheimer’s disease (AD). Given that neurological symptoms are better explained by the topography rather than by the nature of brain lesions, our study aimed to evaluate whether cognitive impairment would be more closely associated with the
-
Amino acid PET vs. RANO MRI for prediction of overall survival in patients with recurrent high grade glioma under bevacizumab therapy Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-17 Artem Chaban, Birgit Waschulzik, Denise Bernhardt, Claire Delbridge, Friederike Schmidt-Graf, Arthur Wagner, Benedikt Wiestler, Wolfgang Weber, Igor Yakushev
-
Impact of patient motion on parametric PET imaging Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-15 Alessia Artesani, Joyce van Sluis, Johannes H. van Snick, Laura Providência, Walter Noordzij, Charalampos Tsoumpas
-
A systematic review for the evidence of recommendations and guidelines in hybrid nuclear cardiovascular imaging Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-15 Florent L. Besson, Giorgio Treglia, Jan Bucerius, Constantinos Anagnostopoulos, Ronny R. Buechel, Marc R. Dweck, Paula A. Erba, Oliver Gaemperli, Alessia Gimelli, Olivier Gheysens, Andor W. J. M. Glaudemans, Gilbert Habib, Fabian Hyafil, Mark Lubberink, Christopher Rischpler, Antti Saraste, Riemer H. J. A. Slart
-
New EAU/ASCO guideline recommendations on sentinel node biopsy for penile cancer and remaining challenges from a nuclear medicine perspective Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-13
Abstract Introduction The European Association of Urology (EAU) and the American Society of Clinical Oncology (ASCO) recently issued updated guidelines on penile cancer, emphasising dynamic sentinel node biopsy (DSNB) as the preferred method for surgical staging among patients with invasive penile tumours and no palpable inguinal lymphadenopathy. This paper outlines the rationale behind this new recommendation
-
First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [68Ga]Ga-HER2 Affibody Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-13 Mingru Zhang, Fei Kang, Tong Xing, Junling Wang, Taoqi Ma, Guiyu Li, Zhiyong Quan, Weidong Yang, Xiaoyuan Chen, Jing Wang
-
First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-12
Abstract Purpose This is a first-in-human study to evaluate the radiation dosimetry of a new prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical, [18F]AlF-P16-093, and also initial investigation of its ability to detect PSMA-positive tumors using PET scans in a cohort of prostate cancer (PCa) patients. Methods The [18F]AlF-P16-093 was automatically synthesized with a GE TRACERlab
-
Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer Eur. J. Nucl. Med. Mol. Imaging (IF 9.1) Pub Date : 2024-01-11 Jisu Kim, Seunghwan Lee, Dongwoo Kim, Hyun Jeong Kim, Kyeong Taek Oh, Sun Jung Kim, Young Deuk Choi, Frederik L. Giesel, Klaus Kopka, Alexander Hoepping, Misu Lee, Mijin Yun